Zhengzhou Handu Pharmaceutical Co. Ltd.

Main purpose: This study uses the empagliflozin tablets (specification: 25 mg) certified by Zhengzhou Handu Pharmaceutical Group Co., Ltd. as the test preparation and the empagliflozin tablets (trade name: Jardiance®, specification: 25 mg) certified by Boehringer Ingelheim International GmbH as the reference preparation to conduct a human bioequivalence test under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: This study used Olopatadine Hydrochloride Tablets certified by Zhengzhou Handu Pharmaceutical Group Co., Ltd. as the test preparation and Olopatadine Hydrochloride Tablets (trade name: Allelock) certified by Kyowa Kirin Co., Ltd. as the reference preparation to conduct a human bioequivalence test under fasting/fed conditions. Secondary purpose: To evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects.

Main purpose: Using the indobufen tablets (specification: 0.2g) certified by Zhengzhou Handu Pharmaceutical Group Co., Ltd. as the test preparation, and the indobufen tablets (trade name: Ibustrin, specification: 0.2g) certified by Pfizer Italia S.r.l. as the reference preparation, a human bioequivalence test was conducted under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.